Cytokine Signalling Forum

CME Courses




« Return to Overview

Signalling: New Approaches to Inflammatory Diseases

Developed by CESAS Medical, under the auspices of the University of Glasgow
This activity is supported by an educational grant from Gilead

Release date: 25 June 2019
Estimated time to complete activity: 1 and 1/2 hours
Compatible with all modern internet browsers and mobile devices

EDUCATIONAL OBJECTIVES
After completing this activity, the learner will be able to:
  • Explain the varied cytokine signalling pathways involved in immune homeostasis, particularly the JAK-STAT pathway and its implication across a variety of inflammatory diseases
  • Describe the mechanisms of action of JAK inhibitors approved and under investigation
  • Compare and contrast JAK inhibitors, both those approved and in development, and their potential therapeutic applications
  • Discuss the evolving disease landscape where JAK inhibitors may deliver benefit

TARGET AUDIENCE
This activity is is designed for rheumatologists and other healthcare professionals involved in treating patients with rheumatic disease.

PROGRAMME OVERVIEW
JAK inhibitors or JAKinibs are evolving as the next generation of therapeutics in the management of rheumatoid arthritis. This programme provides an overview of cytokine signalling in the inflammatory pathway and offers the opportunity to review the current landscape of JAKinibs in rheumatic indications.

In this activity, Signalling: New Approaches to Inflammatory Diseases, a panel of international experts discuss the published data relating to the mechanism of action of JAKinibs and their implications in clinical practice.

Here, we review three core topics relating to JAKinibs: the biological role of cytokine signalling in arthritis pathogenesis; the clinical data on JAK inhibition in rheumatoid arthritis; and the clinical application of JAKinibs beyond RA.

This course, Signalling: New Approaches to Inflammatory Diseases, provides an overview of cytokine signalling in the inflammatory pathway, with a focus on the JAK-STAT pathway, and outlines the key data relating to the role of JAKinibs in the treatment landscape of rheumatoid arthritis and additional rheumatic conditions. The learner’s understanding of the information presented will be assessed following each of the course modules, and in accordance with the learning outcomes.

INSTRUCTIONS FOR PARTICIPATION
Participants must 1) read the activity information; 2) study the educational content; 3) successfully complete the post-module assessments with a score of ≥80%; 4) complete the evaluation form. Upon completion of the full activity, a certificate will be made available to download and print.

DISCLOSURE OF CONFLICTS OF INTEREST
CESAS Medical requires faculty, presenters, planners, managers, writers, and any other individuals who are in a position to influence the content of this activity to disclose any real and/or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly reviewed and resolved according to CESAS Medical policy.

Please note that this course is currently awaiting accreditation.
Module Presenter Video Questions
Introduction
Professor Peter Taylor image
Professor Peter Taylor

Norman Collisson Professor of Musculoskeletal Sciences,
University of Oxford, Oxford, UK

Professor Peter Taylor studied pre-clinical medical sciences at Gonville and Caius College at the University of Cambridge, where he earned his first degree in Physiology. He subsequently studied clinical medicine at the University of Oxford and was awarded a PhD degree from the University of London for studies on the pathogenesis of arthritis. In October 2011, Professor Taylor was appointed Norman Collisson Chair of Musculoskeletal Sciences at the University of Oxford, and is a Fellow of St. Peter's College, Oxford. He is the Head of Clinical Sciences at the Botnar Research Centre within the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences.

He has specialist clinical interests in novel therapies, rheumatoid and early arthritis. His research expertise is in mechanisms sustaining inflammation and clinical trials of new therapies with development of novel outcome measurements for application in assessment of response to therapy.

Prof. Peter Taylor (Bio)
Professor John Isaacs image
Professor John Isaacs

Director of Therapeutics North East, Professor of Clinical Rheumatology,
Newcastle University, Newcastle upon Tyne, UK

Professor John Isaacs is the Director of Therapeutics North East at Newcastle University, and Professor of Clinical Rheumatology. He is also an Honorary Consultant Rheumatologist with the Newcastle-upon-Tyne Hospitals NHS Foundation Trust. He is the Scientific Chair-elect for the European League Against Rheumatism (EULAR). Professor Isaacs’ research interests include immunotherapy of rheumatic, autoimmune disease, therapeutic tolerance induction, pathogenesis of rheumatoid arthritis and genetics and pharmacogenetics of rheumatoid arthritis. His translational research is considered internationally renowned.

Prof. John Isaacs (Bio)
Professor Bruce Kirkham image
Professor Bruce Kirkham

Consultant Rheumatologist; Professor of Translational Rheumatology,
Guys' and St Thomas' NHS Foundation Trust; King's College London

Professor Bruce Kirkham studied medicine in New Zealand, before undertaking rheumatology training at Guy’s Hospital in London. In 1991, he became a Consultant Rheumatologist in Adelaide and Sydney, and in 2000, he was appointed as a Consultant Rheumatologist to the Guy’s and St Thomas’ NHS Foundation Trust in London. Professor Kirkham is also a Professor of Translational Rheumatology at King’s College London. In 2013, he was awarded the Outstanding Best Practice Award by the British Society of Rheumatology, after setting up a service to optimise the care of patients with rheumatoid and psoriatic arthritis. His research is focussed on IL-17/23 pathways in inflammatory arthritis, with an aim of ensuring the best practice for arthritis patients. In 2016, his team was named by GRAPPA as one of seven international best practice centres.

Prof. Bruce Kirkham (Bio)
02:23
The Biologic Role of Cytokine Signalling Pathways and Implications for Arthritis Pathogenesis
Professor John Isaacs image
Professor John Isaacs

Director of Therapeutics North East, Professor of Clinical Rheumatology,
Newcastle University, Newcastle upon Tyne, UK

Professor John Isaacs is the Director of Therapeutics North East at Newcastle University, and Professor of Clinical Rheumatology. He is also an Honorary Consultant Rheumatologist with the Newcastle-upon-Tyne Hospitals NHS Foundation Trust. He is the Scientific Chair-elect for the European League Against Rheumatism (EULAR). Professor Isaacs’ research interests include immunotherapy of rheumatic, autoimmune disease, therapeutic tolerance induction, pathogenesis of rheumatoid arthritis and genetics and pharmacogenetics of rheumatoid arthritis. His translational research is considered internationally renowned.

Prof. John Isaacs (Bio)
17:43 4
Clinical Results from JAK Inhibition in RA – Can We Discern the Pathway from the Profile?
Professor Peter Taylor image
Professor Peter Taylor

Norman Collisson Professor of Musculoskeletal Sciences,
University of Oxford, Oxford, UK

Professor Peter Taylor studied pre-clinical medical sciences at Gonville and Caius College at the University of Cambridge, where he earned his first degree in Physiology. He subsequently studied clinical medicine at the University of Oxford and was awarded a PhD degree from the University of London for studies on the pathogenesis of arthritis. In October 2011, Professor Taylor was appointed Norman Collisson Chair of Musculoskeletal Sciences at the University of Oxford, and is a Fellow of St. Peter's College, Oxford. He is the Head of Clinical Sciences at the Botnar Research Centre within the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences.

He has specialist clinical interests in novel therapies, rheumatoid and early arthritis. His research expertise is in mechanisms sustaining inflammation and clinical trials of new therapies with development of novel outcome measurements for application in assessment of response to therapy.

Prof. Peter Taylor (Bio)
24:21 5
Clinical Application of JAK Inhibitors beyond RA
Professor Bruce Kirkham image
Professor Bruce Kirkham

Consultant Rheumatologist; Professor of Translational Rheumatology,
Guys' and St Thomas' NHS Foundation Trust; King's College London

Professor Bruce Kirkham studied medicine in New Zealand, before undertaking rheumatology training at Guy’s Hospital in London. In 1991, he became a Consultant Rheumatologist in Adelaide and Sydney, and in 2000, he was appointed as a Consultant Rheumatologist to the Guy’s and St Thomas’ NHS Foundation Trust in London. Professor Kirkham is also a Professor of Translational Rheumatology at King’s College London. In 2013, he was awarded the Outstanding Best Practice Award by the British Society of Rheumatology, after setting up a service to optimise the care of patients with rheumatoid and psoriatic arthritis. His research is focussed on IL-17/23 pathways in inflammatory arthritis, with an aim of ensuring the best practice for arthritis patients. In 2016, his team was named by GRAPPA as one of seven international best practice centres.

Prof. Bruce Kirkham (Bio)
34:42 4
Close
Professor Peter Taylor image
Professor Peter Taylor

Norman Collisson Professor of Musculoskeletal Sciences,
University of Oxford, Oxford, UK

Professor Peter Taylor studied pre-clinical medical sciences at Gonville and Caius College at the University of Cambridge, where he earned his first degree in Physiology. He subsequently studied clinical medicine at the University of Oxford and was awarded a PhD degree from the University of London for studies on the pathogenesis of arthritis. In October 2011, Professor Taylor was appointed Norman Collisson Chair of Musculoskeletal Sciences at the University of Oxford, and is a Fellow of St. Peter's College, Oxford. He is the Head of Clinical Sciences at the Botnar Research Centre within the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences.

He has specialist clinical interests in novel therapies, rheumatoid and early arthritis. His research expertise is in mechanisms sustaining inflammation and clinical trials of new therapies with development of novel outcome measurements for application in assessment of response to therapy.

Prof. Peter Taylor (Bio)
Professor John Isaacs image
Professor John Isaacs

Director of Therapeutics North East, Professor of Clinical Rheumatology,
Newcastle University, Newcastle upon Tyne, UK

Professor John Isaacs is the Director of Therapeutics North East at Newcastle University, and Professor of Clinical Rheumatology. He is also an Honorary Consultant Rheumatologist with the Newcastle-upon-Tyne Hospitals NHS Foundation Trust. He is the Scientific Chair-elect for the European League Against Rheumatism (EULAR). Professor Isaacs’ research interests include immunotherapy of rheumatic, autoimmune disease, therapeutic tolerance induction, pathogenesis of rheumatoid arthritis and genetics and pharmacogenetics of rheumatoid arthritis. His translational research is considered internationally renowned.

Prof. John Isaacs (Bio)
Professor Bruce Kirkham image
Professor Bruce Kirkham

Consultant Rheumatologist; Professor of Translational Rheumatology,
Guys' and St Thomas' NHS Foundation Trust; King's College London

Professor Bruce Kirkham studied medicine in New Zealand, before undertaking rheumatology training at Guy’s Hospital in London. In 1991, he became a Consultant Rheumatologist in Adelaide and Sydney, and in 2000, he was appointed as a Consultant Rheumatologist to the Guy’s and St Thomas’ NHS Foundation Trust in London. Professor Kirkham is also a Professor of Translational Rheumatology at King’s College London. In 2013, he was awarded the Outstanding Best Practice Award by the British Society of Rheumatology, after setting up a service to optimise the care of patients with rheumatoid and psoriatic arthritis. His research is focussed on IL-17/23 pathways in inflammatory arthritis, with an aim of ensuring the best practice for arthritis patients. In 2016, his team was named by GRAPPA as one of seven international best practice centres.

Prof. Bruce Kirkham (Bio)
00:40
Evaluation 17

Date of preparation: 25 June 2019